Boehringer Waves White Flag In Humira Patent Battle
Boehringer Ingelheim on Tuesday abandoned its long-shot assault on the patent fortress surrounding AbbVie Inc.'s immunosuppressant Humira, saying it would reluctantly join a long list of biosimilar makers that have agreed...To view the full article, register now.
Already a subscriber? Click here to view full article